Results 71 to 80 of about 11,110 (180)

Phenolic Compounds as Promising Drug Candidates in Tuberculosis Therapy

Molecules, 2019
Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB) remains one of the deadliest, infectious diseases worldwide. The detrimental effects caused by the existing anti-TB drugs to TB patients and the emergence of resistance strains of M ...
Muhamad Harith Mazlun, Siti Fatimah Sabran, Maryati Mohamed, Mohd Fadzelly Abu Bakar, Zunoliza Abdullah   +4 more
doaj   +1 more source

Liposomal Glutathione Exhibits Direct and Intracellular Antimycobacterial Activity Against Mycobacterium avium via Membrane Depolarization in a THP-1 Macrophage Model

Bioengineering
Mycobacterium avium (M. avium) is an opportunistic intracellular pathogen causing chronic pulmonary disease in immunocompromised individuals, particularly in those with HIV/AIDS.
Nezam Newman, Kayvan Sasaninia, Wajiha Akif, Kaylee Dillard, Destiny Jaime, Kaitlyn Nguyen, Malina Navarrette, Jesse Melendez, Iffat Hasnin Era, Ama Xu, Navya Sharma, Syed Muzzammil Ahmad, Rakesh Kumar Tiwari, Vishwanath Venketaraman   +13 more
doaj   +1 more source

Iron-Reversible Bactericidal Activity of Marine-Derived Aspergillus ostianus Hydroxamate Pyrazinones Against Replicating and Hypoxia-Induced Non-Replicating Mycobacterium smegmatis

Marine Drugs
Tuberculosis therapy is prolonged partly because dormant subpopulations of Mycobacterium tuberculosis show reduced susceptibility to first-line drugs. Therefore, agents active against both replicating and non-replicating mycobacteria remain important to ...
Muhammad Azhari, Shinnosuke Isshiki, Riku Horinouchi, Marlia Singgih, Masayoshi Arai, Afrillia Nuryanti Garmana, Rika Hartati, Yuni Elsa Hadisaputri, Nunung Yuniarti, Elin Julianti   +9 more
doaj   +1 more source

Secondary Pulmonary Alveolar Proteinosis Associated With Ruxolitinib After Bone-Marrow Transplantation: A Case With Transient Improvement Following Drug Discontinuation. [PDF]

Respirol Case Rep
Yanagi T, Asami-Noyama M, Yamamoto K, Hoshii Y, Ichiyama Y, Okimura M, Fujii T, Suizu J, Harada M, Murakawa K, Hamada K, Utsunomiya T, Murata Y, Oishi K, Edakuni N, Kakugawa T, Hirano T, Matsunaga K.   +17 more
europepmc   +1 more source

Antimycobacterial peptides as natural therapeutics for tuberculosis: mechanisms and structural features. [PDF]

Front Antibiot
Pritam P, Das S, Behera SK, Sahoo M, Subudhi L, Mohapatra S, Panda AK.   +6 more
europepmc   +1 more source

Fabrication and Antimycobacterial Evaluation of Molybdenum Disulfide-Coated Titanium Alloy Scaffolds. [PDF]

ACS Omega
Hou Y, Lu W, Xu Y, Liu B, Sun Z, Liang T, Zhang X, Chu H.   +7 more
europepmc   +1 more source

Aortoesophageal fistula caused by Mycobacterium bovis following intravesical Bacillus Calmette-Guérin therapy: a case report and literature review. [PDF]

BMC Infect Dis
Koshiba T, Hakamata M, Tomita Y, Yamagishi I, Ui M, Tsuruma H, Bamba Y, Ogata H, Shibata S, Cho H, Sato M, Aoki N, Moro H, Yoshitake A, Kikuchi T.   +14 more
europepmc   +1 more source

4‑Aminoalkylquinolines as Potent Antitubercular Agents Targeting the Cytochrome bc₁ Complex. [PDF]

ACS Med Chem Lett
Grams ES, Ramos AS, da Silva FF, Perelló MA, de Matos Czeczot A, Maia AM, Caetano HA, Altenhofen S, Paz JD, Gonçalves GA, Liu XG, Repasy T, Klein LD, Polesello GP, Sanchez Ferreira CA, de Oliveira SD, Stieler R, Silva SME, Bonan CD, Bizarro CV, Basso LA, Parish T, Machado P.   +22 more
europepmc   +1 more source

Biomarkers and Diagnostic and Therapeutic Approaches for Mycobacterial Diseases. [PDF]

Trop Med Infect Dis
Rizvi A, Gupta Y.
europepmc   +1 more source

Antimycobacterial Peptides: From Natural Product Discovery to AI Guided Design. [PDF]

Biochemistry
Biswas D, Medina SH.
europepmc   +1 more source